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INTRODUCTION

The accepted wisdom within both the academy and among practitioners is that
the goal of multidistrict litigation, or at least its frequent result, is a global
settlement of asserted claims that resolves the litigation. Commentators have
pointed out that the most common result of multidistrict litigation is some form of
settlement and have argued that multidistrict litigation provides a vehicle for
aggregating claims in a manner that can facilitate settlement.2
In many MDL litigations, however, there is no settlement at all. There are a
number of well-publicized instances where MDL courts have disposed of all claims
by granting omnibus motions to dismiss or for summary judgment.3 Accordingly,
consolidation in multidistrict proceedings can serve the valuable function of
resolving common questions that may prove dispositive of the litigation in its
entirety. In other cases, the common questions may dispose of part of the litigation
or shape the litigation in ways that significantly impact the value of the asserted
claims. Such examples alone refute the notion that the end goal of multidistrict
litigation is settlement.
Moreover, even where there is some form of settlement, such settlements
frequently arise only after many of the claims have been eliminated through
dispositive motion practice or after bellwether trials' have shown that the value of

2 See, e.g., RICHARD A. NAGAREDA, MAss TORTS IN A WORLD OF SETTLEMENT
ix (2007) ("As in
traditional tort litigation, the endgame for a mass tort dispute is not trial but settlement."); Andrew D.

Bradt, The Long Arm of Multidistrict Litigation, 59 WM. & MARY L. REV. 1165, 1224 (2018)
[hereinafter Bradt, Long Arm] ("In most large MDLs, what actually happens is that a settlement
agreement is eventually negotiated by the lead lawyers, and it is likely to be one that leaves the plaintiff
little practical choice but to accept."); Andrew D. Bradt, The Shortest Distance: Direct Filing and

Choice of Law in Multidistrict Litigation, 88 NOTRE DAME L. REV. 759, 791 (2012) [hereinafter Bradt,
Shortest Distance] ("[A]s several scholars have noted, like the class action, the key virtue of the MDL is
that is [sic] collects most parties in a single organized proceeding in order to facilitate a global
settlement."); Elizabeth Chamblee Burch, Remanding MultidistrictLitigation, 75 LA. L. REV. 399, 416
(2014) [hereinafter Burch, Remanding] ("[T]he 'settlement culture' for which the federal courts are so
frequently criticized is nowhere more prevalent than in MDL practice." (quoting Delaventura v.

&

Columbia Acorn Trust, 417 F. Supp. 2d 147, 150 (D. Mass. 2006))); Elizabeth Chamblee Burch

Margaret S. Williams, Repeat Players in MultidistrictLitigation: The Social Network, 102 CORNELL L.

REV. 1445, 1447 (2017) [hereinafter Burch & Williams, Repeat Players] ("Even though multidistricting
aims to avoid duplicative pretrialefforts, most cases settle."); Martin H. Redish & Julie M. Karaba, One
Size Doesn't FitAll: Multidistrict Litigation, Due Process, and the DangersofProceduralCollectivism,
95 B.U. L. REV. 109, 128 (2015) ("Settlement is the fate of almost all cases that are part of an MDL....
Parties to MDL cases and the transferee judges who preside over them face tremendous pressure to
settle."); Edward F. Sherman, The MDL Modelfor Resolving Complex Litigation If a Class Action Is

Not Possible, 82 TUL. L. REv. 2205, 2206 n.4 (2008) ("[Mlost multidistrict litigation is settled in the
transferee court.").
See, e.g., Douglas G. Smith, Resolution of Common Questions in MDL Proceedings, 66 U. KAN.

L. REV. 219, 229-30, 232-47 (2017).
' A "bellwether" trial is a mechanism used to test theories of the case and potentially provide
guidance in settlement discussions by assessing how such theories may fare before juries. Id. at 256-57

n.204-06.
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the claims is not particularly great.s While it is true that in such cases the litigation
may be terminated through a global settlement, the settlement may be at a value
that is so low that essentially it amounts to a "loss" for the plaintiffs. Because the
terms of settlements are typically confidential, the outside world may be unable to
ascertain whether the settlements that occur are actually substantial or rather
merely represent a mechanism for terminating the litigation.
This article addresses a phenomenon in MDL proceedings that is more subtle
and frequently less transparent than the effect of dispositive motion practice or
bellwether trials. Many of the claims in MDL proceedings are eliminated-not
based on any ruling on a dispositive motion-but through informal means because
the claims are meritless on their face. 6 Indeed, claims are frequently eliminated
because plaintiffs' counsel agree to voluntarily dismiss them.' Similarly, plaintiffs
may simply fail to produce basic evidence to support the claims. Thus, there is
another-frequently unnoticed-way in which claims are weeded from MDL
proceedings, further undermining the narrative that multidistrict litigation is simply
about reaching settlement.
This phenomenon also illustrates how the myth of settlement surrounding MDL
proceedings has the potential to be profoundly counterproductive. Allowing claims
to go untested because they are aggregated in an MDL proceeding whose alleged
goal is to achieve settlement inevitably results in the compensation of claims with
little or no merit, to the detriment of both defendants and other claimants alike. In
addition, this approach to multidistrict litigation only encourages the filing of
additional frivolous claims. Plaintiffs' counsel may assume that the court is
unlikely to scrutinize the asserted claims, and instead focus on achieving a global
settlement to resolve all claims in the litigation.'
As commentators have observed, this dynamic is contrary to the just resolution
of claims in MDL proceedings, and indeed may lead to the violation of
fundamental principles of due process.' This is no small matter. Litigation in the
federal courts is increasingly being conducted in the context of MDL proceedings.
Estimates of the proportion of cases in the federal system that have been
consolidated for pretrial proceedings in multidistrict litigation run from one-third to
one-half of all federal cases."o Thus, flaws in the MDL process inevitably will have
a significant impact on civil justice within the federal court system.
s See, e.g., id at 256 ("[P]laintiffs' counsel typically seek to try selected 'bellwether' cases as soon
as possible in order to use the results of such trials to pressure defendants into global settlements.").
6 See id

at 254.

'See id.

8

See, e.g., Hon. Eduardo C. Robreno, The Federal Asbestos Product Liability Multidistrict

Litigation (ADL-875): Black Hole or New Paradigm?, 23 WIDENER L.J. 97, 187 (2013) (noting that

.

"aggregation promotes the filing of cases of uncertain merit" and that "[t]he incentive becomes the
number of cases that can be filed, not the relative merit of the individual case").
' See, e.g., Redish & Karaba, supra note 2, at 151 (contending that "MDL, as currently structured.
. infringes on individual claimants' procedural due process rights"); Robreno, supra note 8, at 187
(noting "the significant due process issues raised by forcing parties to litigate or settle cases in groups").
1n See, e.g., Andrew D. Bradt & D. Theodore Rave, The Information-ForcingRole of the Judge in
MultidistrictLitigation, 105 CALIF. L. REv. 1259, 1259 (2017) (noting that "more than one third of the
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The fact of the matter is that, because of the growing significance of MDL
litigation, such proceedings are increasingly the subject of debate within both the
academic community and the legal community in general." Numerous recent
articles have been published in law reviews describing these phenomena.1 2
Proposals for statutory reform of the MDL process have been introduced in
Congress." And, increasingly, judges and practitioners are becoming cognizant of
the flaws in the MDL system.
Fortunately, in many cases, MDL courts and litigants have utilized the tools
available in MDL proceedings to address these issues and weed out claims that
have no merit. As noted, dispositive motion practice is one way in which courts
have resolved common issues that dictate the outcome of all, or large categories of,
claims filed in MDL proceedings.1 4 This article focuses on the more informal
mechanisms that have been employed, which frequently fly below the radar, and
which typically give more individualized treatment to claims filed in MDL
proceedings. These may include informal resolution through discussion between
plaintiff and defense counsel, identification of unsupported claims through Lone
Pine" and show cause orders, or dispositive motions filed in individual cases
pending in the MDL proceedings that can influence whether plaintiffs pursue other,
similarly-situated cases.
Part I discusses the problems associated with aggregation in MDL proceedings.
Aggregation tends to encourage the filing of meritless claims for a variety of
federal civil caseload is MDL"); Bradt, Shortest Distance, supra note 2, at 784 ("[O]ne third of all civil
cases in the federal courts right now are part of a pending MDL."); Elizabeth Chamblee Burch,
Monopolies in MultidistrictLitigation, 70 VAND. L. REV. 67, 72 (2017) [hereinafter Burch, Monopolies]
("[F]rom 2002 to 2015, multidistrict proceedings leapt from sixteen to thirty-nine percent of the federal
courts' entire civil caseload. Removing prisoner and social security cases escalates that number to 45.6
percent."); Eldon E. Fallon et al., Bellwether Trials in MultidistrictLitigation, 82 TUL. L. REV. 2323,
2324 (2008) ("In an age of increasing skepticism regarding the use of class actions in our legal regime,
the modem multidistrict litigation (MDL) process embodied in 28 U.S.C. § 1407 is emerging as the
primary vehicle for the resolution of complex civil cases."); DUKE LAW SCH. CTR. FOR JUDICIAL
STUDIES,

MDL

STANDARDS

AND

BEST

PRACTICES

xi

(2014),

https://judicialstudies.duke.edulsites/default/files/centers/judicialstudies/MDLStandards and
BestPractices_2014-REVISED.pdf
[https://perma.cc/GJH5-35R9]
(noting that "MDLs
represented 45.6% of the pending civil cases as of June 2014").
" See, e.g., Bradt, Long Arm, supra note 2; Andrew D. Bradt, "A Radical Proposal": The
Multidistrict Litigation Act of 1968, 165 U. PA. L. REV. 831 (2017) [hereinafter Bradt, "A Radical
Proposal"]; Elizabeth Chamblee Burch, Judging MultidistrictLitigation, 90 N.Y.U. L. REV. 71 (2015)
[hereinafter Burch, Judging]; Burch, Remanding, supra note 2; S. Todd Brown, PlaintiffControl and
Domination in MultidistrictMass Torts, 61 CLEV. ST. L. REV. 391 (2013).
12 See sources cited supra notes 2, 11.
" See, e.g., Fairness in Class Action Litigation and Furthering Asbestos Claim
Transparency Act of 2017, H.R. 985, 115th Cong. § 102(2) (2017) (stating that one of the
purposes of the Act was to "diminish abuses in class action and mass tort litigation that are
undermining the integrity of the U.S. legal system").
' See Smith, supra note 3, at 252-53, 256.
is Lore v. Lone Pine Corp., No. L-33606-85, 1986 WL 637507, at *1 (N.J. Super. Ct. Law Div.
Nov. 18, 1986). A Lone Pine order is one that requires plaintiffs to provide basic information regarding
their claims at the outset of the litigation, including potentially an affidavit from a medical expert
supporting each plaintiff's claim. Smith, supra note 3, at 230.
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reasons, including the reduction of individual scrutiny received by claims that are
pending in aggregated proceedings. As a result, there are many instances in which
multidistrict litigations have been inundated with claims that have later been
eliminated because they lacked merit.
Part II provides examples of MDL proceedings in which large numbers of
claims have been resolved through informal mechanisms. These mechanisms may
complement dispositive motion practice in resolving claims at the pretrial stage
before bellwether selection. The examples discussed in Part II illustrate that many
different and varied procedures have been employed by the courts and the parties to
eliminate meritless claims.
Part ll addresses some of the implications of these examples. These examples
show that assessment of claims at an early stage in the litigation is critical to the
fair and efficient resolution of multidistrict proceedings. Simply driving toward
settlement is not an option where large numbers of invalid claims are allowed to
linger in MDL proceedings, and indeed such claims can actually frustrate
settlement. Settlement efforts may be impaired because defendants are unwilling to
pay for a universe of claims that the defendants know are meritless. Settlement can
also be frustrated in more indirect ways; for example, the presence of large
numbers of meritless claims can interfere with the selection of representative cases
for bellwether trials. Such examples also illustrate that settlement is not the only, or
even the primary, outcome in many MDL proceedings. In addition to those MDL
proceedings that are completely resolved through dispositive motion practice,
significant progress frequently is made in resolving MDL proceedings through
these less formal mechanisms.
I. THE PROBLEM WITH MDL AGGREGATION

The problems that arise in MDL proceedings are akin to those that arise in all
proceedings in which claims are aggregated: aggregation tends to incentivize the
filing of claims of dubious merit. There are many reasons for this phenomenon and
many potential causes.
A. FactorsLeading to Meritless Claims
The most obvious cause of the problem is the financial incentive plaintiff
lawyers have to maximize their returns. The more claims that are filed, the greater
the potential recovery." A secondary incentive is that a firm's inventory of claims
is often a key determinant of its role in the MDL proceedings. Typically, MDL
courts establish a plaintiff steering committee, and membership on that committee
may be driven in large part by the number of claims-and therefore financial

16

See Smith, supra note 3, at 219 ("[TJhere is an incentive for plaintiffs' counsel to include more and more
claims that are not meritorious, in order to increase their own fees and influence in the proceedings.").
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interest-a firm has in the litigation.1 7 Accordingly, with a larger inventory of
claims comes a greater chance of having a more significant role in the proceedings.
Perhaps a slightly more charitable explanation for the recognized fact that many
claims in MDL proceedings lack merit is that the larger the volume of claims, the
more difficult it becomes for the lawyers to adequately screen the claims before
filing them. MDL claims are frequently the result of mass-advertising campaigns
that encourage members of the public to file claims if they believe they have been
injured with the incentive of payment with little effort on their part." As a result,
law firms may be inundated with large numbers of claims that they must screen
before filing. The extent to which, and the effectiveness with which, these firms
screen the claims that come in the door may vary among firms. Nonetheless, while
counsel have an ethical obligation to refrain from filing frivolous cases, 9 many are
filed anyway-potentially evidencing a failure to properly screen them.
Another factor leading to the proliferation of meritless claims in MDL
proceedings is closely tied to aggregation. When claims are aggregated before a
decisionmaker with finite resources, inevitably claims will receive less scrutiny
than if they are filed with multiple decisionmakers. One hundred claims filed with
one judge inevitably will receive less scrutiny than the same claims filed with one
hundred or even fifty judges. Knowing that this is the case, plaintiff counsel may
file claims that they would not otherwise file, believing that they will not receive
the scrutiny that they would otherwise receive outside an MDL proceeding. 20
Finally, and perhaps most importantly, the belief that MDL proceedings
inevitably will result in settlement rather than robust litigation of asserted claims
can only further incentivize plaintiff counsel to file claims that lack merit. 21
Comfortable in the belief that the merits of the claims will never be subjected to
scrutiny, plaintiff counsel are much more likely to file claims that simply lack
merit. As one MDL judge recently observed, "[s]ome lawyers seem to think that
their case will be swept into the MDL where a global settlement will be reached,
allowing them to obtain a recovery without the individual merit of their case being

1 See BOLCH JUDICIAL INSTITUTE, DUKE LAW SCH., GUIDELINES AND PRACTICES FOR LARGE AND
MASS-TORT MDLS 33-34 (2d ed., 2018).
' See Bexis, The Multi-DisrbictLitigation Statute Need Rewriting, DRUG & DEVICE LAW (Dec. 19, 2016),
https://www.dniganddevicelawblog.com/2016/12/the-multi-district-hltigation-staute-needs-rewriting.htmli

[bttps://pena.c/8MBS-9FB5].
19 MODEL RULES OF PROF'L CONDUCT AND CODE OF JUDICIAL CONDUCT

§ 3.1

(AM. BAR ASSN 2016).

20 See Smith, supra note 3, at 231 (recognizing the concern "that aggregating claims in an MDL

proceeding allows plaintiffs' counsel to shield frivolous claims from scrutiny by lumping them with
other claims and avoiding individualized treatment").
21 See Burch, Remanding, supra note 2, at 402 ("[P]laintiffs' attorneys can bypass doctrinal
uncertainties over weak claims by packaging plaintiffs together in a global settlement."); see also id. at
413 ("[M]ultidistrict litigation coaxes claimants out of the woodwork regardless of their claim's strength
in hopes of initially staying buried under mounting cases then cashing in on settlement."); Barbara J.

Rothstein et al., A Model Mass Tort: The PPA Experience, 54 DRAKE L. REv. 621, 622 (2006)
("[A]ttempts to aggregate similar, though not identical, claims through class actions or global
settlements cause an unfortunate blurring of the merits of individual claims, often resulting in
overcompensation for weak claims and undercompensation for strong claims.").
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scrutinized as closely as it would if it proceeded as a separate individual action." 22
Thus, to the extent the settlement narrative is perpetuated in MDL proceedings, it is
likely to have a profoundly negative effect-incentivizing counsel to file meritless
claims at the expense of both defendants and those plaintiffs whose claims have
merit.23
B. Recognition of the Problem
These problems are no secret among the bar and judges who have gone through
the process of resolving complex MDL proceedings. Commentators have
repeatedly noted the dubious nature of many claims filed in mass tort MDLs in
particular. 24 As one judge recently observed: "MDL consolidation for products
liability actions does have the unintended consequence of producing more new case
filings of marginal merit in federal court, many of which would not have been filed
otherwise." 25

The recognition of the problem has led to calls for formalized rule or statutory
changes to make it easier to weed out frivolous claims filed in MDL proceedings.
These reforms have included proposals for more formalized procedures at the
beginning of MDL cases requiring the production of basic information needed to
establish plaintiffs' claims. 26 They have also included proposals for increased
22 In re Mentor Corp. Obtape Transobturator Sling Prods. Liab. Litig., No. 4:08-MD-2004, 2016
WL 4705827, at *1 (M.D. Ga. Sept. 7, 2016).

23 At least one commentator has argued that MDL judges have an incentive to encourage settlement
that is bound up with their reputation among the judiciary, and specifically with the Judicial Panel on

Multidistrict Litigation, which has the authority to assign them (or not) to future MDL cases. See Burch,
Remanding, supra note 2, at 417-18, 421 ("[F]ailing to resolve cases quickly can subject transferee
judges to scrutiny from the Panel.... So, transferee judges have their own professional and reputational
incentives to broker deals and thwart remand.... As long as the Panel continues to 'reward' transferee
judges who quickly settle cases with new multidistrict litigation assignments and quietly bemoan the
rest, transferee judges will prefer to keep assignments as long as it takes to browbeat the parties into
settling."); see also Burch, Judging, supra note 11, at 83-84 ("[T]he Panel views quickly settling a
complex case as a hallmark of success that disposes it to reward that judge with new litigation.").
24 See, e.g., Advisory Comm. on Civil Rules, MDL Subcommittee, Notes of February 28, 2018
Conference Call, in ADVISORY COMMITTEE ON CIVIL RULES: PHILADELPHIA, PA; APR. 10,

2018, at 157, 161 (2018), https://www.uscourts.gov/sites/default/files/2018-04-civil-rulesagenda-book.pdf [https://perma.cc/M7V4-QN5S] ("There are simply too many claims 'parked' in
MDL proceedings that would never be presented, or survive early motion practice, as individual
actions."); Civil Rules Advisory Comm., Draft Minutes of the November 7, 2017 Meeting of the
Advisory Committee on Civil Rules, in ADVISORY COMMITTEE ON CIVIL RULES: PHILADELPHIA, PA;

APR. 10, 2018, at 67, 91 (2018), httpsJAvww.uscourts.gov/sites/default/files/2018-04-ivil-mles-agendabook.pdf [httpsi//permacc/M7V4-QN5S] ("The problem is the frivolous cases, not the 'gray-area' cases. Reliable
sources suggest that in big MDLs of some types 20% or more of the claims are 'zeroed out."').
2 In re Mentor Corp., 2016 WL 4705827, at *2. The Judicial Panel on Multidistrict Litigation,
which is responsible for establishing MDL proceedings, has also noted the problem: "The response to
such concerns more properly inheres in assigning all related actions to one judge committed to disposing
of spurious claims quickly." In re Seroquel Prods. Liab. Litig., 447 F. Supp. 2d 1376, 1379 (J.P.MIL. 2006).
26 See, e.g., BOLCH JUDICIAL INSTITUTE, DUKE LAW SCH., supra note 17, at 9 ("[R]equiring

plaintiffs at an early juncture to produce information verifying their basic factual allegations addresses
concerns that MDL proceedings invite unsubstantiated claims.").
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access to interlocutory appellate review of decisions made by MDL courts so that
appellate courts may provide guidance to MDL judges to ensure that rigorous
standards are applied.2 7
Legislative proposals have been introduced in Congress to embody such
reforms in formal statutes.2 8 The Advisory Committee on Civil Rules has also
considered proposals for changes to the Federal Rules in order to address the
problem.29 Finally, projects such as the Bolch Judicial Institute's Guidelines and
Best Practicesfor Large and Mass-Tort MDLs have sought to outline best practices
for MDL proceedings short of formal amendment of rules or statutes.30 All of these
efforts are in response to an acknowledged problem: the large number of facially
meritless claims that are filed in large MDL proceedings.
H.

MECHANISMS THAT HAvE BEEN USED TO ADDRESS THE PROBLEM

When one examines actual practice in MDL proceedings, it becomes clear that
settlement is not inevitable. As noted, many MDLs are resolved in whole or in part
through dispositive motion practice.' Large MDLs such as the Meridia, PPA, and
Norplant MDLs have been resolved in whole or large part through rulings on
motions for summary judgment.32 Recent examples of MDLs where claims were

27 See, e.g., Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of

2017, H.R. 985, 115th Cong. § 105(k)(1) (2017).
28 See, e.g., id. (establishing procedural standards and limits for class action cases).
29 See Civil Rules Advisory Comm., supra note 24, at 86-95.
30

See BOLCH JUDICIAL INSTITUTE, DUKE LAW ScH., supra note 17, at ix.

See Rothstein et al., supra note 21, at 638 (observing that motions for summary judgment and Daubert
motions "are a major vehicle for reducing meritless claims in a large litigation"); Bradt, Long Arm, supra note 2, at
1172-73 (noting that "in the recent nationwide products liability MDL involving the drug Zolof, the MDL court
granted summary judgment against 333 transferred cases in one fell swoop").
32 See In re Lipitor (Atorvastatin Calcium) Mktg., Sales Practices and Prods. Liab. Litig. (No II)
MDL 2502, 892 F.3d 624, 649 (4th Cir. 2018) (affirming grant of summary judgment in product
liability actions involving statins); In re Zoloft (Sertraline Hydrochloride) Prods. Liab. Litig., 858 F.3d
787, 800 (3d Cir. 2017) (affirming summary judgment on all claims); In re Fosamax (Alendronate
Sodium) Prods. Liab. Litig. (No. I), 751 F.3d 150, 164 (3d Cir. 2014) (affirming holding that claims
against generic manufacturers of pharmaceuticals were preempted by federal law); Meridia Prods. Liab.
Litig. v. Abbott Labs., 447 F.3d 861, 869 (6th Cir. 2006) (affirming grant of summary judgment as to all
claims in MDL); In re Temporomandibular Joint (TMJ) Implants Prods. Liab. Litig., 113 F.3d 1484,
1498 (8th Cir. 1997) (affirming summary judgment in favor of the supplier of silicone gel used in
implants); In re Mirena IUD Prods. Liab. Litig., 202 F. Supp. 3d 304, 327-28 (S.D.N.Y. 2016)
(excluding various expert opinions in MDL, leading to a grant of summary judgment); In re
Phenylpropanolamine (PPA) Prods. Liab. Litig., 289 F. Supp. 2d 1230, 1251 (W.D. Wash. 2003)
(excluding evidence regarding alleged causative link between phenylpropanolamine (PPA) and
hemorrhagic or ischemic stroke where plaintiffs had not taken the medication within seventy-two hours
of their stroke and further excluding expert evidence regarding any causal link between PPA and all
other alleged injuries such as seizures, cardiac injuries, and psychoses); In re Norplant Contraceptive
Prods. Liab. Litig., 215 F. Supp. 2d 795, 828-29 (E.D. Tex. 2002) (holding that, under the learned
intermediary doctrine, claims relating to the twenty-six conditions contained in contraceptive labeling
were barred as a matter of law); In re Indep. Serv. Orgs. Antitrust Litig., 964 F. Supp. 1479, 1491 (D.
Kan. 1997) (granting dispositive motion on antitrust claims).
31
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decided entirely, or in large part, through dispositive motion practice provide an
illustration of how such mechanisms work to resolve aggregated litigation.
In the Lipitor MDL proceedings, for example, the court rejected most of the
claims filed in the MDL after finding that there was no reliable scientific evidence
to support them." While plaintiffs maintained that the defendant's cholesterol
medication increased the risk of developing Type 2 diabetes, the court concluded
that the proffered evidence was not scientifically reliable.34 Accordingly, the court
granted Dauberts motions to exclude plaintiffs' expert evidence, concluding that
the claims were "not based on sufficient facts and data." 3 6
Specifically, the court in Lipitor held that there was no reliable scientific
evidence establishing a statistically significant relationship between the medication
and diabetes for the vast majority of the doses on the market.37 Indeed, the studies
found no statistically significant association between these doses and diabetes,
tending to refute any causal relationship.3 8 Moreover, the court concluded that the
remaining "evidence" plaintiffs had submitted, such as alleged "admissions" by the
defendant, were insufficient to establish that there was any causal relationship.39
In Mirena, the court issued a painstaking opinion rejecting all claims in the
MDL, parsing through each proffered expert's opinion and concluding that there
was no reliable scientific evidence to support the litigation.40 The issue there was
whether defendant's JUTD was defective, resulting in migration of the device and
perforation of the uterus.41 In excluding plaintiffs' scientific evidence, the court
concluded that the plaintiffs' expert's theory "ha[d] never been tested or studied in
human patients, nor ha[d] it undergone animal or in vitro testing"4 2 or "gained
'general acceptance' within the scientific community."4 3 The court determined that
the plaintiffs' expert was essentially "given a conclusion by lawyers" and then
"worked backwards to hypothesize a mechanism by which it might occur."" As the
court observed, however, there were "just too many gaps between [the expert's]
analysis and the conclusions" the expert drew from the evidence.45 Without reliable

33 See In re Lipitor (Atorvastatin Calcium) Mktg., Sales Practices and Prods. Liab. Litig., 227 F.

Supp. 3d 452,491 (D.S.C. 2017), af'd, 892 F.3d 624 (4th Cir. 2018).
34
Id. at 456, 462.
" Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579 (1993). "Daubert provides the analytical
framework for determining whether expert testimony is admissible under Rule 702 of the Federal Rules

of Evidence." In re Silica Prods. Liab. Litig., 398 F. Supp. 2d 563, 620-21 (S.D. Tex. 2005).
36 In re Lipitor, 227 F. Supp. 3d at 463, 491.
17 See id. at 463.
38 Id. at 463, 482-83.

3 Id at 479-84.
' See In re Mirena IUD Prods. Liab. Litig., 202 F. Supp. 3d 304, 327-28 (S.D.N.Y. 2016).
41 Id. at 305.
42 In re Mirena IUD Prods. Liab. Litig., 169 F. Supp. 3d 396, 429 (S.D.N.Y. 2016).
43 Id. at 429-30 (quoting Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579, 594 (1993)).
4 Id. at 430.
45 Id. at 445.
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evidence of causation, plaintiffs were unable to establish a fundamental element of
their claims, and the court granted summary judgment.46
Such decisions are not mere anomalies. There are many instances in which
MDL judges have resolved all or a large portion of asserted claims through
dispositive pretrial motion practice. There are frequently issues that are common
among asserted claims that can be resolved through omnibus motion practice.4 7
Whether, for example, a product causes a particular injury or condition often turns
on scientific evidence that is uniform with respect to the asserted claims. Issues like
this and others are amenable to resolution on a common basis in a proceeding
where claims are aggregated. Such procedures are an effective means of resolving
MDL litigation and, contrary to the settlement narrative, have been employed
repeatedly.
However, there are other, less formalized procedures that are frequently
employed to eliminate large numbers of claims in MDL proceedings. These
procedures tend to be more individualized in nature, going through claims on a
claim-by-claim basis and eliminating the claims that have no merit for various
reasons." It may be that product liability plaintiffs lack evidence of exposure to the
product asserted. It may be that they lack evidence that they actually suffered the
injury they alleged in the complaint. It may be that, for a variety of case-specific
reasons, it is unlikely that the product at issue actually caused their particular
injury. It may be that the claims are legally flawed based on the particular state law
that governs the claims. Or there may be defenses like the statute of limitations that
bar the claims on their face.
The elimination of claims using such procedures often occurs under the radar.
Indeed, many dismissals may be obtained on a voluntary basis where defendants
provide evidence of the claims' insufficiency to plaintiffs' counsel who then agree
to eliminate the claims.4 9 Other dismissals may be obtained through motion
practice.so And yet other claims may be eliminated through simple inaction by
plaintiffs in producing information required by established MDL procedures, such
as by failing to adequately complete a plaintiff fact sheet" or providing medical
records or other discovery required by the MDL court.52 In sum, there is a large
diversity in the ways in which such claims may be eliminated, and frequently this
4 In re Mlrena, 202 F. Supp. 3d at 327-28 (rejecting plaintiffs' efforts to substitute purported "admissions" in

company documents, labeling, or other materials for reliable scientific evidence ofcausation).
47 Smith, supra note 3, at 229 ("The standard way in which such issues are resolved is at the outset
of the litigation through omnibus motions to dismiss or for summary judgment on all, or specific
categories of, claims.").
48 See infra notes 53-152 and accompanying text.
'9 See Smith, supra note 3, at 254 ("In some cases, plaintiffs' counsel may agree to dismissal in
order to avoid scrutiny of their claims by the court.").
5o BOLCH JUDICIAL INSTITUTE, DUKE LAW SCH., supra note 17, at 67 ("The [MDL] litigation may

be resolved through motion practice that results in a dismissal by the court, or rulings that effectively
end the litigation.").
s' See, e.g., In re Phenylpropanolamine (PPA) Prods. Liab. Litig., 460 F.3d 1217, 1239-40 (9th Cir. 2006).
52 See Smith, supra note 3, at 254 ("[I]t is standard practice to require that plaintiffs produce their
medical records so that the claims can be evaluated.").
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phenomenon is underappreciated given the less than transparent way it often
manifests itself in MDL proceedings.
A. In re Heparin: Voluntary Dismissal
Many MDL proceedings have combined dispositive motion practice as to
common issues with more informal means of eliminating claims. In the Heparin
MDL proceedings, the court granted summary judgment on several issues that
eliminated most of the claims in the litigation." Plaintiffs alleged that contaminated
heparin, an anticoagulant, given to patients with end-stage renal disease and
patients undergoing coronary artery bypass surgery was responsible for a range of
adverse health conditions, including death.54 The court eliminated several
categories of these claims because they were not based on reliable scientific
evidence." The court ruled, among other things, that plaintiffs lacked sufficiently
reliable scientific evidence that the contaminated heparin could be associated with
these conditions if the conditions occurred more than sixty minutes after receipt of
heparin.5 6
Less formal proceedings, however, also led to the resolution of many claims
filed in the MDL proceedings. For example, one significant issue in the
proceedings was whether plaintiffs actually received contaminated heparin that was
manufactured by defendants." Only certain lots during a limited period of time
were potentially contaminated." Many plaintiffs who filed claims did not receive
contaminated heparin, or at least it was very unlikely that they received
contaminated heparin." Others did not even receive heparin manufactured by the
defendants in the MDL, but rather likely received heparin produced by other

s In re Heparin Prods. Liab. Litig., 803 F. Supp. 2d 712, 755 (N.D. Ohio 2011).
4
Id. at 719-21.
" Id. at 753.
56 Id. at 738-39, 753. The Centers for Disease Control and Prevention had performed a study
examining adverse events that occurred after administration, which found that the events that seemed to
be occurring were anaphylactoid events that occurred within sixty minutes of administration of heparin
that contained contamination. Id. at 721-23. This study, and the absence of contrary epidemiological
evidence, supported the court's ruling that plaintiffs' expert opinions lacked any scientific basis and
were inadmissible under Rule 702 and Daubert. See id. at 753. The court determined that mechanistic
arguments based on in vitro or animal studies could not overcome the lack of epidemiological evidence
supporting plaintiffs' claims. See id. at 738-39. The court noted that plaintiffs' expert had "shown that
there is increased kallikrein activity, but her opinion that this activity can have effects beyond the
sixty-minute time period is speculative." Id. at 739.
1 See, e.g., Dodson v. Baxter Intern., Inc. (In re Heparin Prods. Liab. Litig.), No. 1:09HC60020,

2009 WL 2916888 (N.D. Ohio Sept. 4, 2009); Schweikert v. Baxter Healthcare Corp. (In re Heparin
Prods. Liab. Litig.), No. 1:10HC60154, 2012 WL 1944805 (N.D. Ohio Mar. 6, 2012).
" See In re Heparin Prods. Liab. Litig., 803 F. Supp. 2d 712, 721 (N.D. Ohio 2011) (discussing
recall of particular lots and fact that "severe adverse reactions associated with heparin were reported
between November, 2007, and January, 2008").
5

E.g., Schweikert, 2012 WL 1944805, at *1 (finding that one shipment received by hospital

occurred "before distribution of any contaminated heparin" and with respect to second shipment,
"plaintiff has shown no proof that it was from a contaminated lot").
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manufacturers.6 0 Using information regarding batches that contained contamination

along with shipping information, claims that were unlikely associated with
contamination could be identified.6' Once such claims were identified, plaintiffs'
counsel frequently dismissed them voluntarily.
Where necessary, defendants filed motions for summary judgment in the
individual cases.62 The MDL court expeditiously dealt with these motions and, as a
consequence, plaintiffs' counsel who might have been reticent to voluntarily
dismiss meritless claims began doing so in order to avoid the spotlight shining on
the meritless claims by the individual motion practice. As a result, while there was
some up-front investment of time by the court (which could have been avoided had
plaintiffs' counsel been more compliant), it paid dividends as plaintiffs' counsel
began to voluntarily dismiss claims that should not have been filed in the first
place. Between dispositive motion practice and these more informal procedures,
more than half of the claims that were filed in the MDL were eliminated.6 1
The Heparin proceedings illustrate how informal mechanisms may lead to the
resolution of hundreds of claims without intervention by the court or the
expenditure of judicial resources. Plaintiffs' counsel typically seek to avoid alerting
the court that they have filed claims of dubious merit. Where, as in Heparin, the
facts or the law demonstrate that plaintiffs' claims on their face have no merit,
plaintiffs' counsel have an incentive to agree to eliminate those claims rather than
litigating them in front of the court. This incentive, of course, is counterbalanced by
the incentive to maximize potential financial returns and the likelihood of obtaining

' E.g., Dodson, 2009 WL 2916888, at *2 (granting summary judgment because undisputed
evidence showed the heparin plaintiff received "could not have been manufactured by Baxter," but
rather was made by another manufacturer, APP).
61 See, e.g., id. (conducting analysis and granting summary judgment on plaintiffs claims);
Schweikert, 2012 WL 1944805, at *1 (conducting analysis and granting summary judgment on
plaintiff's claims).
62 See generally, e.g., Schweikert, 2012 WL 1944805 (granting defendants' motion for summary
judgment based on the lack of proof of exposure to contaminated heparin); Dodson, 2009 WL 291688
(granting defendants' motion for summary judgment based on the lack of proof of exposure to
contaminated heparin); Nya v. Baxter Int'l Inc. (In re Heparin Prods. Liab. Litig.), No. 3:14HC60000,
2014 WL 11515374 (N.D. Ohio Nov. 3, 2014) (summary judgment granted where "no proof' plaintiff
"received contaminated heparin"); Fioretti v. Baxter Healthcare Corp. (In re Heparin Prods. Liab.
Litig.), No. LO-10-2824, 2011 WL 5-23904 (N.D. Ohio Oct. 19, 2011) (summary judgment granted
where "no proof" plaintiff "received contaminated heparin").
6 Interview with S. Donnell, counsel of record in the Heparin MDL (April 2019); Smith, supra
note 3, at 236 (noting that more than 50% of claims were eliminated through generic motion practice
alone). In addition to its ruling regarding the timing of the adverse events following administration, the
court also held that certain adverse events such as sepsis-related events were not associated with
contaminated heparin. In re Heparin, 803 F. Supp. 2d at 738. The court further determined that the
adverse events that might be associated with contamination occurred with a very specific type of
administration. Id. at 739-40. The court noted that studies had indicated that such adverse events
typically occurred with intravenous administration of heparin, as opposed to subcutaneous
administration, and therefore held that there was no reliable scientific evidence to support claims based
on the latter method of administration. Id. As the court noted, there was "simply too great an analytical
gap between" the expert's opinions and the data on which they were based. Id. at 740 (quoting Gen.
Elec. Co. v. Joiner, 522 U.S. 136, 146 (1997)).
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a leadership role in the MDL by filing as many claims as possible. Nonetheless, in
many instances, claims may be dismissed voluntarily without the need for the court
to intervene, and if they are not, then the filing of a few motions in individual cases
frequently provides an incentive to plaintiffs' counsel to cooperate without the need
for the resolution of individual motions in every case.
B. In re Mentor Corp.: Show Cause Orders and Threat of Sanctions
Another mechanism by which claims may be eliminated short of formal motion
practice is through show cause orders or similar procedures. In the Mentor MDL
proceedings, for example, the court implemented such an approach as a means of
dealing with the volume of meritless claims that had been filed in the MDL
proceedings."4
The Mentor MDL involved claims alleging that a mesh sling used to treat
patients with stress urinary incontinence was defective, leading to a variety of
adverse medical conditions.6 ' As the court observed, after the MDL was
established with twenty-two cases, claims "exploded to more than 850 cases, which
explosion appears to have been fueled, at least in part, by an onslaught of lawyer
television solicitations.'66
After reviewing the claims, the court concluded that plaintiffs' counsel in the
MDL had filed numerous claims that they "should have known" lacked any "good
faith basis" because they were "clearly barred by the applicable statute of
limitations," plaintiffs' counsel were "unable to identify a specific causation
expert," or "counsel threw in the towel and did not even bother to respond to [a]
summary judgment motion."' The court warned plaintiffs' counsel that if it were
forced to decide summary judgment motions on cases that lacked a good faith basis
in the future, the court would issue show cause orders as to why sanctions should
not be imposed. 69 Accordingly, the court provided that "in future orders granting
summary judgment in which no good faith basis existed for maintaining the action
through the summary judgment stage, the Court intends to include an addendum in
the order requiring counsel to show cause why sanctions should not be imposed."o
The Mentor MDL provided something of an education for the trial court. As in
many MDLs, while a court may initially provide plaintiffs the benefit of the doubt,
believing that plaintiffs' counsel have adequately investigated claims before they
file them, once the proceedings progress to a certain point and the court actually
begins to review individual claims, frequently there is a realization that this is not
. See In re Mentor Corp. Obtape Transobturator Sling Prods. Liab. Litig., 4:08-MD-2004, 2016
WL 4705827, at *1 (M.D. Ga. Sept. 7, 2016).
65 In re Mentor Corp. Obtape Transobturator Sling Prods. Liab. Litig., 711 F. Supp. 2d 1348, 1353
(M.D. Ga. 2010).
66
In re Mentor Corp., 2016 WL 4705827, at *1 n.2.
6
Id. at *1.
6s Id.
69 Id.

7o Id.
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the case. Given the benefit of its own experience, the court sought to inform other
members of the judiciary that, as a general matter, "transferee judges should be
aware that they may need to consider approaches that weed out non-meritorious
cases early, efficiently, and justly." 71 The court in the Mentor MDL believed that
the use of sanctions was an appropriate tool to deal with the problem, hoping that
"the robust use of Rule 11" would "help" to eliminate and deter such filings. 72
The court, however, also employed other mechanisms to eliminate claims in
addition to the threat of Rule 11 sanctions. The court noted that, in addition to the
one hundred separate summary judgment rulings the court had already issued,
seventy-four cases had been "dismissed voluntarily by the plaintiffs via notice of
voluntary dismissal or a motion to dismiss" and that an additional 458 cases were
either "dismissed by stipulation of the parties" or by "order of dismissal following
a notice of settlement."73 Accordingly, as in other MDL proceedings, voluntary
dismissal of claims by plaintiffs' counsel was a significant mechanism for weeding
out invalid claims. 74 Implementation of judicially-supervised procedures, such as
the sanctions mechanism employed in the Mentor MDL, can further encourage the
elimination of claims through voluntary measures.
C. In re Silica: Review ofDiagnoses and Sanctions
One of the most widely-publicized examples of an MDL that went off the rails
due to the rampant filing of meritless claims is the Silica proceeding.75 There,
plaintiffs alleged that they had developed silicosis, an impairment of the respiratory
system they claimed was associated with exposure to respirable silica during the
course of their occupations as sandblasters, foundry workers, and members of other
trades.76 As the court began to explore the claims, however, it quickly became
apparent that the diagnoses of the plaintiffs were the result of unreliable and
medically invalid procedures, if not widespread fraud. As Judge Jack observed

n Id. at *2.
72 Id.

7 Id. at *1 n.2.
74 See id

71 In re Silica Prods. Liab. Litig., 398 F. Supp. 2d 563 (S.D. Tex. 2005). Many other scholars have
discussed the Silica case as illustrative of the problems in the MDL system. See, e.g., Brown, supra note
11, at 425 ("[A]fter the threatened demise of asbestos litigation triggered a rush to file silicosis claims,
thousands of asbestos plaintiffs were 'recycled' as silicosis plaintiffs."); Mark A. Behrens & Corey
Schaecher, Rand Institutefor Civil Justice Report on the Abuse ofMedical DiagnosticPracticesin Mass
Tort Litigation: Lessons Learned from the "Phantom" Silica Epidemic that May Deter Litigation

Screening Abuse, 73 ALB. L. REv. 521 (2010); Robreno, supra note 8, at 121 ("Judge Jack had
conducted Daubert hearings and determined that almost all of the silicosis cases on her MDL docket
were fraudulent.").
76 In re Silica, 398 F. Supp. 2d at 569, 569-73.
n See id at 635.
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after evaluating the claims, they appeared to be "driven by neither health nor
justice: they were manufactured for money." 8
First, as Judge Jack noted, the sheer volume of claims alone demonstrated that
there was a problem." There were so many claims filed beyond what would have
been expected that there "appear[ed] to be a phantom epidemic, unnoticed by
everyone other than those enmeshed in the legal system."so Moreover, the claims
were concentrated in certain states where litigation was filed before the MDL was
created.8
As the court investigated, it found that the diagnoses of the plaintiffs were not
made by the plaintiffs' treating physicians.82 Rather, they were made by "the same
handful" of physicians affiliated with screening companies that plaintiffs' counsel
had retained for the purpose of the litigation.83 These doctors purported to have
reviewed literally thousands of cases. As the court noted, "over 9,000 Plaintiffs
who submitted Fact Sheets were diagnosed with silicosis by only 12 doctors." 84 As
a result, the court described these reports as being "essentially manufactured on an
assembly line."
The court utilized the mechanism of a Dauberthearing to dig into the problem,
ordering that the diagnoses be subject to review under Rule 702 and Daubert." In
preparation for the hearing, the parties conducted discovery into the methodology
the doctors followed in providing the diagnoses, deposing the doctors and obtaining
records regarding the procedures they followed.87 This discovery demonstrated that
there were significant problems.
As a threshold matter, the doctors repeatedly testified that they did not actually
diagnose any plaintiff with silicosis, and indeed in some instances indicated that
they had never diagnosed any patient with silicosis and did not know the criteria for
doing so. 8 Rather, as one doctor noted, he simply reviewed plaintiffs' chest

7 Id. ("The record does not reveal who originally devised this scheme, but it is clear that the
lawyers, doctors and screening companies were all willing participants.").
7 See id. at 572.
o Id. at 572-73. As the court observed, one small screening company "found 400 times more
silicosis cases than the Mayo Clinic (which sees 250,000 patients a year) treated during the same
period." Id. at 603; see also id. at 620 (concluding that "there simply is no rational medical explanation
for the number of alleged diagnoses of silicosis in this MDL").
" Id. at 573-74 (noting that many plaintiffs in the MDL cases were citizens of Mississippi,
Alabama, and Texas).

82

Id. at 580.

" Id. at 580, 633 ("[W]hen it comes to the doctors who diagnosed these Plaintiffs with
silicosis, 12 names appear.").
14 Id at 580.

Id. at 633.
Id. at 620-22; see also Nora Freeman Engstrom, RetaliatoryRICO and the Puzzle of Fraudulent
Claiming, 115 MICH. L. REv. 639, 677 (2017) ("[I]t was a Daubert motion Judge Jack used to uncover
fraud in the Silica MDL, which brought that potentially costly litigation to an early end.").
87 In re Silica, 398 F. Supp. 2d at 580-94.
88
Id at 581, 588 (observing that doctors admitted "they had never diagnosed anyone with silicosis").
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x-rays.89 These and other statements contradicted the "reports" that were submitted
on the experts' behalf.90
Because there were so many cases to review, the amount of time that the
physicians spent reviewing the materials was exceedingly small. Physicians would
provide as many as seventy-five "diagnoses" in a single day." Moreover, the
exposure histories on which they relied were generally taken by individuals who
had "no medical training" and had "significant financial incentives to find someone
positive for exposure to silica" because they were lawyers for plaintiffs or the
lawyers' clerks. 92 Accordingly, the court concluded that "[t]he steps in the
diagnosing process were divided among a number of different people, not all of
whom were qualified and none of whom assumed overall responsibility and
oversight for the entire process."93
The court concluded that the entire process was largely driven by the lawyers
and legal considerations, rather than medical or scientific principles:
If nothing else, this MDL illustrates the mess that results when
lawyers practice medicine and doctors practice law. In almost all of
these cases, one vital requirement for the diagnosis of silicosis-the
taking of occupational histories-was performed absent medical
oversight by the lawyers or their agents or contractors. More generally,
the lawyers determined first what disease they would search for and then
what criteria would be used for diagnosing that disease.

Conversely, virtually all of the challenged diagnosing doctors
seemed to be under the impression they were practicing law rather than
medicine. They referred to the Plaintiffs as "clients" rather than
"patients", and they utilized shockingly relaxed standards of diagnosing
that they would never have employed94 on themselves, their families or
their patients in their clinical practices.
As a result, the court found that the diagnoses were fundamentally unreliable and
95
failed the Dauberttest.

9

Id. at 581.

Id. at 588 (noting that two "doctors testified that, contrary to the language in the typed forms,
they did not see any x-rays, x-ray reports or pulmonary function tests, and they did not diagnose any
Plaintiff with silicosis").
9' Id. at 582.
92 Id. at 622, 624 ("[T]he evidence shows that none of the challenged experts took an
occupational or exposure history. They all relied upon a history taken by lawyers and clerks
with no medical training or supervision.").
93 Id. at 633.
94 Id. at 634-35.
9 Id. at 625.
90
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The results of the investigation the court conducted found that many of the
plaintiffs were simply former asbestos plaintiffs whom the plaintiff law firms
sought to transform into silicosis plaintiffs using this screening process. 96 As the
court observed, there were a "staggering number" of silica plaintiffs who had
previously filed asbestosis claims.97 Yet, as the court noted, silicosis and asbestosis
were distinct diseases with distinct causes that were seldom observed together in a
single patient. 98
Finally, the physicians failed to take into account alternative explanations for
the observations they made with respect to the plaintiffs' x-rays.99 The court found
that "[i]n almost all of the MDL cases, the challenged diagnosing doctors simply
ignored this final criterion (i.e., the absence of any good reason to believe that the
positive radiographic findings are the result of some other condition) altogether.""
Again, the doctors' failure to follow any reliable methodology further demonstrated
that they were not really "diagnosing" plaintiffs with any disease.ioi
As a result of its investigation, the court ended up imposing sanctions, ordering
payment of expenses and costs associated with the Daubert hearings that led to the
court's rulings. 102 Indeed, confronted with the evidence, at least one physician felt
that he needed to obtain legal representation before he could continue to provide
testimony.' 03 As the court observed, in addition to harming defendants, the filing of
meritless claims also harmed those plaintiffs who had claims that potentially had
merit: "every meritless claim that is settled takes money away from Plaintiffs
whose claims have merit."'0

96 Id. at 628. The problems in the Silica litigation stemmed in part from the fact that plaintiffs were
seeking to recycle asbestos claimants as silica claimants. See id. As one commentator observed:
Some double dippers (some 6,000, in fact) sought fumds from both silica and
asbestos manufacturers and therefore claimed (in separate filings) that they were suffering
from silicosis or, alternatively, asbestosis, despite the fact that the two diseases have different
sources of exposure, on x-rays look "vastly different," and are very rarely found in the same

individual.
Engstrom, supra note 86, at 659.
9 In re Silica, 398 F. Supp. 2d at 628.
9 Id. at 594-95, 628-29.
9 Id. at 630 (finding that the doctors' failure to take into account alternative explanations for x-ray
observations "clearly is not generally accepted in the field of occupational medicine").
100 Id. at 629-30. The court noted that "[e]ach lawyer had to know that he or she was filing at least
some claims that falsely alleged silicosis." Id. at 636.
i'' See id. at 633.

Id. at 676-78, 680.
Id. at 607.
104 Id. at 636. The Silica litigation is not the only litigation in which courts have uncovered
problems with the diagnoses of plaintiffs. As noted below, the court uncovered a similar
102
103

problem in the In re Welding Fume proceedings with respect to the diagnosis of Parkinson's
disease. See TED FRANK, WELDING FUME: A DISAPPEARING MASS TORT? 9 (2007), httpsi/fedsoc-

cms-public.s3.amazonaws.com/update/pdf/nlLcuj8dSjZeopO77pYsPlquYXdJnsmwMpcEHJIl.pdf
[https://penna.cc/C6KH-QL3J]. Similarly, in the fen-phen litigation, there were medically unsupported
diagnoses of heart valve damage by a small number of physicians. Engstrom, supra note 86, at 656-57
("[T]he lead plaintiffs' lawyer for the fen-phen class alleged that a stunning 70 percent of class
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D. In re Welding Fume: Requiring Diagnosisby Independent Physicians
A similar phenomenon occurred in the Welding Fume MDL. Just as in Silica,
mass screenings resulted in thousands of meritless claims that were eventually
dismissed.' 0 The Welding Fume litigation involved claims alleging that exposure
to fumes from defendants' welding products was associated with Parkinson's
disease and other neurological conditions." Much like the Silica litigation, the
plaintiffs in the Welding Fume litigation were typically not diagnosed with an
alleged injury by their treating physicians. Rather, they were diagnosed through
mass screenings sponsored by plaintiffs' counsel.'o7 In fact, of the plaintiffs
alleging they had Parkinson's disease, "more than seventy percent of the plaintiffs
diagnosed with this condition were diagnosed by the same doctor." 08
As with many multidistrict proceedings in which courts fail to implement
procedures for early scrutiny of claims, the court began to understand the
magnitude of the problem when the parties began selecting bellwether cases for
trial.'" As these individual cases came under scrutiny, the evidence showed that
individuals who claimed they were "disabled" were actually far from it, and that
there were instances of what appeared to be outright fraud."o One powerful
indicator of the meritless nature of the claims was that the vast majority of the
plaintiffs who were diagnosed through these mass screenings never sought any
treatment for their alleged conditions."'
Influenced by these events, the court put in place a critical order requiring that
all plaintiffs come forward with a diagnosis by an independent physician
supporting their claims by a court-imposed deadline or have their claims
dismissed." 2 In response to this order, thousands of plaintiffs simply dropped their
lawsuits." 3 Accordingly, the Welding Fume litigation again illustrates the relative
claimants had diagnoses for severe heart-valve damage that were 'medically unfounded and unjustified
because the claimant doesn't have the condition."').
' FRANK, supra note 104, at 9, 12.
106 See Tamraz v. Lincoln Elec. Co., 620 F.3d 665, 667 (6th Cir. 2010).
107 FRANK, supra note 104, at 9 ("Almost all the plaintiffs in the litigation were diagnosed at mass
medico-legal screenings, in which plaintiff-hired neurologists conducted five-minute examinations and
then diagnosed thousands of welders with this rare disorder.").

1os Id.
109 See, e.g., Tamraz, 620 F.3d at 667 ("The district court selected Tamraz's case for one of several
bellwether trials to guide the resolution of the other cases.").
no See FRANK, supra note 104, at 10 ("[P]laintiffs have dismissed three cases selected for early
trials in the MDL proceeding after defendants learned that the plaintiffs had provided false responses in
their discovery responses.").

11i Id.
112 Case Administration Order, In re Welding Fume Prods. Liab. Litig., No. 1:03-CV-17000
(N.D. Ohio 2006).
113 FRANK, supra note 104, at 9 ("[Defendants] have achieved dismissal of thousands of claims
through a case administration order . , . ."); id. at 11 ("Since the CAO was entered, plaintiffs have
moved to dismiss more than 1,000 cases rather than submit Notices confirming that a physician actually
diagnosed the claimant with a welding-related injury.").
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ease with which courts can weed out claims that lack merit from multidistrict
litigation. Simply requiring plaintiffs to produce evidence that they must ordinarily
produce in any normal, individual litigation resulted in the elimination of a large
portion of the cases in the MDL." 4
In addition, the proceeding also illustrates that ultimately no one benefits from
litigation populated by meritless claims. While the vast majority of the claims in
the litigation were voluntarily dismissed, several went to trial both within the
multidistrict proceedings and outside the proceedings. Almost all of the trials,
however, resulted in defense verdicts."' Accordingly, while procedures were
implemented belatedly to weed out many of the claims in the litigation, the
litigation nonetheless imposed significant costs on the judicial system.
E. In re Asbestos: Assisted Review UtilizingMagistrateJudges
Procedures for eliminating individual claims on a case-by-case basis have been
employed effectively even in the most massive MDL proceedings. In the federal
asbestos product liability MDL-which has been characterized as "the largest
MDL in terms of number of claims and cases historically""-the court established
procedures to facilitate individual review by placing each case "on an individual
scheduling order setting forth ... fixed deadlines for completion of discovery and
filing of dispositive motions."" 7
Like many MDL proceedings, the Asbestos MDL began with an orientation
toward settlement. As the federal judge presiding over the MDL observed, the
establishment of the multidistrict litigation for asbestos claims "inspired hope for a
global and comprehensive settlement.""' No such settlement emerged, however,
and the court went about establishing a process to address the tens of thousands of
asbestos claims that were transferred to the MDL proceedings.11 9 In large part, this
entailed claim-by-claim adjudication given that the issues frequently involved
whether there was adequate evidence of exposure to each defendant's products, injury,
and specific causation in each plaintiffs case. 2 0 The court developed procedures to
address the mass of claims in this MDL of unprecedented size and scope, illustrating in

1" The court's order resembles the sort of Lone Pine orders that have been entered in many mass
tort cases to require plaintiffs to provide expert evidence supporting their claims before they may

proceed. See, e.g., In re Zimmer NexGen Knee Implant Prods. Liab. Litig., No. 1:11 -CV-05468, 2016
WL 3281032, at *1 (N.D. Ill. 2016); In re Fosamax Prods. Liab. Litig., No. 06-MD-1789(JFK), 2012
WL 5877418, at *2 (S.D.N.Y. 2012); In re Vioxx Prods. Liab. Litig., 557 F. Supp. 2d 741, 744 45
(E.D. La. 2008); In re Rezulin Prods. Liab. Litig., No. 00 Civ. 2843(LAK), 2005 WL 1105067, at *1
(S.D.N.Y. 2005).
115 FRANK, supra note 104, at 9 ("There have been seventeen welding fume trials in state and
federal court over the last several years. Sixteen have resulted in defense verdicts.").
116 Robreno, supra note 8, at 100 n.4.
117
11

Id. at 127.
' Id. at 112.

119 Id. at 112, 126-27 (discussing how each claim had to be "disaggregated" and reviewed based on
the principle of "one plaintiff-one claim").
120

See id. at 118-19, 127.
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the process that the MDL mechanism could indeed be used to scrutinize even the tens
of thousands of claims that the court confronted in the Asbestos litigation.121
Such procedures were critical in the Asbestos MDL because, much like the
Silica litigation, diagnoses were frequently the result of mass screenings of dubious
validity. 2 2 As Judge Robreno, who presided over the Asbestos MDL, observed,
"'[t]he rate of "positive" findings by these doctors can be startlingly high, often
upwards of 50% and in some studies as high as 90%,' suggesting that the readings
may not be neutral or legitimate."l 23 As Judge Robreno noted, the entire process
was more of a litigation-driven exercise than one driven by medicine or
science: "During litigation screenings, doctors acting in the capacity of 'litigation
consultants,' and not as treating physicians, determined whether the screening
indicated a positive result."l 24 The artificial nature of the review generated many claims
that could not survive judicial scrutiny.1 25 Without such scrutiny, aggregation in an
MDL proceeding would result in the payment of meritless claims at the expense of both
defendants and plaintiffs whose claims potentially had merit'1 26
The court utilized magistrates to assist with the processing of the massive
number of cases filed in the Asbestos proceeding.1 27 Through show cause orders,
"[t]he court required, among other things, each plaintiff to submit medical reports

121
22

1

'"

See id. at I10-12.
Id. at 120-21.
Id. at 121 (quoting AM. BAR Ass'N COMM. ON ASBESTOS LITIG., REPORT TO THE HOUSE OF

DELEGATES 8 (2003), https://www.cdc.gov/niosh/docket/archive/pdfs/niosh-015/020103-exhibitl2.pdf

[https://perma.cc/VEH4-YEUY].
24
1 Id. at 120-21.
125 See id.

126 Rothstein et al., supranote 21, at 622-23; see Robreno, supra note 8, at 120-21,
137 (discussing
the issues with false claims and the procedure created by the court to scrutinize claims). As Judge
Robreno noted, the track record in the asbestos litigation before he was designated to preside over the
Asbestos MDL evidenced such problems: "After nearly twenty years of intensive litigation in the federal
courts, it seemed apparent to the court that efforts toward aggregation of cases and consolidation of
claims had proven ineffective." Id. at 126. When he was appointed to preside over the existing Asbestos
MDL, he found several problems with aggregation:

Aggregation stopped progress on individual cases while the parties and the court worked
on global solutions. Once the global solutions proved unfeasible, the parties did not return to
the task of processing the cases individually. Ultimately, neither the court nor the parties were
ready, willing, or able to move cases to trial and settlement. This stage of litigation led some
litigants to refer to MDL-875 as a "black hole," where cases disappeared forever from the
active dockets of the court.

Id

127 Robreno, supra note 8, at 128. As the MDL judge later noted, the reliance on other personnel is

not really unusual in the context of MDL proceedings:
While, of course, the adjudicating role remains the sole responsibility of the district
judge, the duties and burden of administrating a large MDL must be shared with other
judicial officers and retained professionals. Therefore, the court must recruit and rely upon
magistrate judges, special masters, other administrative personnel, the Clerk's Office staff, IT
specialists, and law clerks for the administration of the case.

Id. at 188.
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based on 'medically accepted principles and practices' along with a complete
exposure history to support their claims or face dismissal."l 28 In addition, plaintiffs
had to identify the products to which they were exposed and the defendants against
whom they were filing a claim.1 29
"In response, some plaintiffs voluntarily dismissed their claims, while defendants
challenged the compliance of other plaintiffs."' 30 Magistrate judges assisted the court in
reviewing the remaining claims by conducting Daubertand other evidentiary hearings
where, for example, defendants challenged the evidence plaintiffs submitted to show
asbestos-related impairmentl 3 ' Cases that were not voluntarily or involuntarily
dismissed, or that were not resolved through the Daubert and evidentiary hearings,
"proceeded to discovery and summary judgment"' 3 2 The court concluded that these
procedures were efficient, given the MDL court's familiarity with the litigation, and
that they "would provide predictability and consistency."'33 With the aid of such
procedures, the court was able to resolve over 183,000 cases. 34
The Asbestos MDL refutes the notion that cases pending in MDLs are inevitably
"litigated as a group."' This was by any measure one of the largest MDLs, and yet the
claims in the Asbestos MDL were uniformly resolved on a case-by-case basis based on
the facts and circumstances of each case.' 36 If individualized adjudication of claims was
possible in the Asbestos MDL, it is possible in any MDL proceeding.
Indeed, an examination of precedent demonstrates that it is more accurate to say
that MDLs "combin[e] aspects of individual and group litigation."'" In fact, it is critical
in MDLs that courts not lose track of the individual nature of the claims. Just as it is
important in MDLs for the courts to address common issues-and in fact that is the
rationale for such a proceeding' 3 8-so too, it is important for courts to continue to
resolve claims on an individualized basis. Claims are transferred to the MDL court for
"pretrial proceedings"' 3 9-not for resolution of common issues only. In order to fairly
and effectively resolve the MDL proceeding, courts must also pay attention to
individual issues with respect to individual claims, as evidenced by the numerous
examples provided herein.

128 Smith, supra note 3, at 255 (quoting Robreno, supra note 8, at 137-38).
129 Robreno, supra note 8, at 138-39.
13o

Smith, supranote 3, at 255.

13' Robreno, supra note

8, at 140.
Id. at 141.
133 Id see also id at 143 ("The key to the successful execution of the summary judgment procedure was the
MDL court's adherence to a rigorous schedule for all cases.. . .Setting a goal line for the MDL litigation, that is,
the time for filing a motion for summary judgment, and thereafter deciding the motions promptly, provided
encouragement to counsel to litigate the case diligently in the MDL or to settle.").
134 Id. at 180 (noting that "since 2006, there have been 186,524 cases transferred to MDL-875" and
that "[o]f those cases, 183,545 have been resolved").
132

135 Bradt, Long Arm, supra note 2, at 1207.
16 Robreno, supra note 8, at 100 n.4, 127.
1" Bradt, Long Arm, supra note 2, at 1206.

.3. See 28 U.S.C. § 1407(a) (2012).
Id.; see also In re Plumbing Fixture Cases, 298 F. Supp. 484, 494 (J.P.M.L. 1968) ("[A]ll
judicial proceedings before trial are pretrial proceedings.").
1"
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F. In re Propulsid Settlement Criteria
Finally, an examination of MDL precedent demonstrates that in some sense a
review of individual claims is almost inevitable in a multidistrict proceeding. If
such a review is not done from the outset of the MDL-the best and most efficient
approachl 40-in many instances, it will be done in the context of settlement. 141 The
PropulsidMDL, for example, utilized procedures that, far from ideally, provided
scrutiny to asserted claims at the settlement stage. There, the parties agreed that
asserted claims would be reviewed by a panel of physicians jointly selected by the
parties' counsel to ensure that the plaintiffs met certain criteria before receiving
settlement funds. 142 When those claims were subjected to independent expert
review, however, it soon became clear that the vast majority of asserted claims had
no merit.1 43 As a result, while plaintiffs' counsel received tens of millions of dollars
in fees, very little of the settlement funds were distributed to the plaintiffs
themselves because their claims did not merit compensation.'"
The Propulsid MDL involved allegations that a medication used to treat
nocturnal heartburn symptoms was associated with heart irregularities.1 45 After the
parties selected bellwethers and conducted bellwether trials, they negotiated a
settlement agreement that established a fund for the compensation of claimants, but
required that the individual claims be subjected to medical review by a panel of
neutral experts.' 4 6 While there were 6,012 plaintiffs who opted for the settlement
process, only thirty-seven of those claimants survived the medical review
process.1 47 As a result, out of an $87 million fund, plaintiffs received
approximately $6.5 million in settlement proceeds, while the lead lawyers received
"over $27 million in common-benefit fees."'48 While the oversized award to
plaintiffs' counsel compared to the award to plaintiffs in the MDL has been
criticized,' 49 it is a function of the fact that the vast majority of the claims filed in
the MDL had no merit.
There are likely many other examples where a significant proportion of
plaintiffs are unable to satisfy settlement criteria. In many instances, however, such

14 See Robreno supra note 8, at 187 (discussing lessons learned from the Asbestos case, including
the necessity of reviewing individual cases at an early stage).
"' See id. at 112, 133.
142 Fallon et al., supra note 10, at 2333-34; see also Consent Order, In re Propulsid Prods. Liab. Litig., 2004
WL 305816, at *2 (E.D. La. 2004) (stating court's intention "to terminate MDL plaintiff and claimant rights to sue
defendants ... if the Medical Panel decides that they are not entitled to compensation).
14 See Burch, Monopolies, supra note 10, at 74-75.
44
' See id.
`5 Fallon et. al., supra note 10, at 2332-33.
146 Id. at 2332-34.
14' Burch, Monopolies, supra note 10, at 74-75.
148 id.
4
' See id These were not the only procedures utilized in the MDL that resulted in the elimination of claims.
For instance, the court dismissed several claims filed by plaintiffs who missed the deadline for submitting their
patient profile forms. See PropulsidMDL Judge Dismisses 92 Casesfor Noncompliance: In re PropulsidProds.

Liab. Litig., 7 ANDREwS DRUG RECALL LMG. REP., no. 2, Sept 2003, at 8.
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information is confidential.Iso Nonetheless, glimpses of the problem are provided in
the literature, 1 and more complete disclosure might provide a greater window into
the failures of the multidistrict litigation system to weed out such claims before the
settlement stage. As the examples above demonstrate, several courts have engaged
in such efforts, demonstrating both their feasibility and actual widespread use.
Nonetheless, there has arguably been a lack of publicity regarding these successes.
As a result, a myth is perpetuated that the goal of multidistrict litigation is
settlement. This myth, along with the corresponding failure to weed out meritless
claims, is counterproductive and damaging to the MDL process.
While it is good that there are examples where settlement criteria and
corresponding review have been used to prevent non-meritorious claims from
receiving settlement compensation, such examples arguably represent a failure of
the system. Claims should be weeded from the beginning of the process-not the
end. As noted below, the failure to provide early scrutiny of submitted claims
interferes with the entire bellwether process.' 52 Moreover, as in Propulsid, it can
result in rewarding plaintiffs' counsel with tens of millions of dollars in fees for
populating the federal court docket with thousands of claims that have no merit.
Such compensation only encourages counterproductive behavior and leads to the
filing of meritless claims in ever increasing numbers.

m.

LESSONS LEARNED

The failure to weed out meritless claims at the outset of an MDL proceeding
can have a significant adverse impact on the course of a multidistrict litigation
proceeding. For example, in many large MDL proceedings, courts preside over
"bellwether" trials to attempt to ascertain the strength of the asserted claims."'
These trials involve test cases that are selected to be "representative" of the body of
cases filed in the multidistrict proceeding. 154 When the body of claims includes

is See Amy L. Saack, Note, Global Settlements in Non-Class MDL Mass Torts, 21 LEwIS & CLARK
L. REv. 847, 857 (2017) ("[I]t is not unusual for Master Settlement Agreements in non-class MDLs to
be confidential.").
15' There are many examples where settlement funds have been inundated with unsupported claims.
See S. Todd Brown, Specious Claims and Global Settlements, 42 U. MEMPIs L. REv. 559, 560-64
(2012). For instance, in the fen-phen litigation, "once people began to suspect that bogus claims were
inundating the $3.75 billion settlement trust, Judge Harvey Bartle ordered an audit of all claims,
ultimately resulting in many denials." Engstrom, supra note 86, at 679. Similarly, in the Vioxx MDL
settlement, over 30% of the asserted claims were unable to fulfill the requirements for obtaining
settlement payments, which included a qualifying injury, minimum use of Vioxx, and use within
a time period proximate to the alleged injury. Transcript of Status Conference at 19-20, 22-23,

In re Vioxx Prods. Liab. Litig., No. 05-MD-1657-L

(E.D.

La.

2010) (No. 05-1657),

http://www.laed.uscourts.gov/sites/default/files/vioxx/Transcripts/0727 10.transcript.pdf

[https://perma.cc/5RSB-NRRS].
' See discussion infra Section Ill.
'15 See Fallon et al., supra note 10, at 2337-38 (describing the bellwether process and noting that,

"[i]n the MDL setting, bellwether trials can be effectively employed for nonbinding informational
purposes and for testing various theories and defenses in a trial setting").

' 4 Id. at 2325.
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many that are frivolous in nature, however, the process frequently breaks down.iss
Plaintiffs' counsel will not want to take cases to trial that they know they will lose,
and which defendants will then hold up as "representative" of the remainder of the
claims. Accordingly, as in the Welding Fume litigation discussed above," 6
plaintiffs' counsel frequently end up dismissing weak claims that happen to be
selected through the bellwether process, and, if plaintiffs' counsel do not
voluntarily dismiss such claims, the court may do so through rulings on pretrial
The inclusion of large numbers of meritless claims in an MDL
motions.'
proceeding thus interferes with the parties' ability to select bellwethers in the first
instance and, more fundamentally, casts doubt on the entire process."'
As one MDL judge has observed, such flaws in the bellwether selection process
can result in it having "a limited global impact":
If bellwether trials are to serve their twin goals as informative
indicators of future trends and catalysts for an ultimate resolution, the
transferee court and the attorneys must carefully construct the trialselection process. Ideally, the trial-selection process should accurately
reflect the individual categories of cases that comprise the MDL in toto,
illustrate the likelihood of success and measure of damages within each
respective category, and illuminate the forensic and practical challenges
of presenting certain types of cases to a jury. Any trial-selection process
that strays from this path will likely resolve only a few independent
59
cases and have a limited global impact.
Neither plaintiffs nor defendants can have any confidence in the "representative"
nature of bellwether trials where the population of claims includes a significant
fraction that should never have been filed.
Likewise, populating the MDL docket with meritless claims can hamper
settlement efforts." No defendant will want to pay money for claims of dubious
merit, and the fact that such claims are included on the MDL docket only increases

1ss See FRANK,

supra note 104, at 10-12.
See supra Section II.D.
's? In the Propulsidlitigation, for example, the court dismissed one of three selected bellwethers on
the ground that "the plaintiff could not state a claim because her alleged gastric problems predated her
1s6

use of Propulsid." Fallon et al., supra note 10, at 2333 (citing In re Propulsid Prods. Liab. Litig., 2003
WL 367739, at *1 (E.D. La. 2003)).
15 As Judge Fallon has noted:
A bellwether trial is most effective when it can accurately inform future trends and
effectuate an ultimate culmination to the litigation; therefore, it is imperative to know what
types of cases comprise the MDL. Otherwise, the transferee court and the attorneys risk
trying an anomalous case, thereby wasting substantial amounts of both time and money.

Id. at 2344.
59
' Id. at 2343.
.o See D. Theodore Rave, Closure Provisions in MDL Settlements, 85 FORDHAM L.
REV. 2175, 2179 (2017).
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the uncertainty of the value of the claims inventory.' Likewise, the failure to weed
out these invalid claims creates inherent conflicts among the plaintiffs and their
counsel.1 6 2 To the extent the strength of claims varies by firm, there may be
conflicts among those firms that have a weaker inventory of claims and those that
have a stronger inventory. Similarly, there is likely a fundamental conflict among the
plaintiffs themselves. Claimants with legitimate claims will not want their recovery
watered down by payments to plaintiffs that never had valid claims to begin
with. Accordingly, even if the goal of the MDL process were settlement
-and this article argues that it should not be, particularly to the exclusion of actually
testing the merits of asserted claims-that goal is fundamentally impaired when the
MDL court fails to provide the required scrutiny to the claims filed in the proceeding.' 63
More generally, the failure to apply judicial scrutiny to claims that are
aggregated in multidistrict litigation inevitably results in bogging down the process
and hindering progress in the resolution of the litigation.'" One of the "lessons
learned" identified by Judge Robreno after presiding over the massive Asbestos
MDL was that such scrutiny of claims is critical at an early stage in the proceeding:
Regardless of the amount of judicial effort and resources, unless the
court establishes a toll gate at which entrance to the litigation is
controlled, non-meritorious cases will clog the process. Therefore, courts
must establish procedures by which, at an early point, each plaintiff is
required to provide facts which support the claim through expert
diagnostics reports or risk dismissal of the case.' 6 5
As the examples above illustrate, the mechanisms for achieving such scrutiny are
diverse in nature. MDL courts have utilized a variety of mechanisms to collect
information and weed out claims that lack merit Nonetheless, as these examples also
illustrate, doing so is critical in achieving progress in a multidistrict proceeding.
161

Id. at 2183.

See Bradt & Rave, supranote 10, at 1266-67.
The measures that courts have taken to weed out claims are also consistent with the general tenor
and goals of the Federal Rules of Civil Procedure. For instance, FRCP 16 encourages federal courts to
use their case management authority to "formulat[e] and simplify[] the issues, and eliminat[e] frivolous
claims or defenses." FED. R. Civ. P. 16(c)(2)(A). This includes "limiting the use of testimony under
Federal Rule of Evidence 702." FED. R. Civ. P. 16(c)(2)(D). It also includes "controlling and scheduling
discovery, including orders affecting disclosures and discovery under Rule 26 and Rules 29 through 37."
FED. R. Civ. P. 16(c)(2)(F).
1 Robreno, supra note 8, at 126, 186.
165 Id. at 186-87. Early attention to the elimination of meritless claims is also consistent with the
Federal Rules of Civil Procedure. For example, the comments to FRCP 16 explain that "a mandatory
scheduling order encourages the court to become involved in case management early in the litigation,"
and that "the fixing of time limits serves to stimulate litigants to narrow the areas of inquiry and
advocacy to those they believe are truly relevant and material." Notes of Advisory Committee on 1983
Amendments, FED. R. Civ. P. 16(b). The drafters hoped to "promot[e] efficiency and conserv[e] judicial
resources by identifying the real issues prior to trial, thereby saving time and expense for everyone."
Notes of Advisory Committee on 1983 Amendments, FED. R. Civ. P. 16(c)(1). The rule contemplates
that such narrowing of the issues need not "await a formal motion for summary judgment" and may be
accomplished by stipulation. Id.
162

163
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Moreover, in many ways, typical procedures employed in MDLs are set up to
facilitate early scrutiny of claims. Courts generally require early disclosure of key
information for all claims, including approving fact sheets that require the
disclosure of support for basic elements of plaintiffs' claims and the disclosure of
medical records where plaintiffs allege some form of personal injury." Thus,
defendants generally have in their possession information that can be used to
provide the sort of scrutiny described in the proceedings above.
As the Judicial Panel on Multidistrict Litigation has observed, individualized
scrutiny of claims may actually be facilitated by the centralization that occurs in an
MDL proceeding."' While the individual facts and circumstances of each case may
differ, an MDL court will soon become familiar with the sorts of fact patterns
found among the individual claims and thus will be in a better position to provide
the sort of scrutiny that would ordinarily occur if the claims remained separate
before different federal judges.
CONCLUSION

MDL proceedings are becoming increasingly important. The percentage of
federal cases being litigated within the confines of multidistrict proceedings
continues to grow. A potential impediment to the full utilization of the MDL
procedure, however, is the notion that the fundamental goal of such proceedings is
to achieve a global settlement. As the examples presented herein demonstrate, early
scrutiny of individual claims is critical to the fair and efficient resolution of an
MDL proceeding. In many MDLs, a large percentage of the claims that are filed
have no merit. The failure of MDL courts to weed out such claims can significantly
impair the effective resolution of such proceedings.
Conversely, as prior MDLs demonstrate, there are a number of different
mechanisms that can be used to provide scrutiny to asserted claims and which, in
fact, have been utilized to eliminate thousands of claims that lacked merit in a
variety of different MDL proceedings. The MDL courts and the parties themselves
have demonstrated that there are a number of creative mechanisms to provide
scrutiny to claims filed in MDL proceedings. Routine utilization of these and other
procedures by MDL courts will only increase the effectiveness of the MDL
procedure.

1'

Smith, supra note 3, at 230; DUKE LAW SCH. CTR. FOR JUDICIAL STUDIES, supra note 10, at

11-12 ("One of the most useful and efficient initial mechanisms for obtaining individual plaintiff
discovery is the use of fact sheets.... Similarly, requiring the collection of plaintiffs' medical records
(in personal injury cases) or employment histories (in employment cases) is another straightforward way
that MDL courts can encourage a robust exchange of key information at a relatively early stage.").
"6 As the Panel has noted: "[T]he transferee court handling several cases in an MDL likely is in a
better position-and certainly is in no worse position than courts in multiple districts handling
individual cases-to properly address meritless claims. There are many tools a transferee court may use
to accomplish this task." In re Cook Med., Inc., IVC Filters Mktg., Sales Practices and Prods. Liab.
Litig., 53 F. Supp. 3d 1379, 1381 (J.P.M.L. 2014).

